<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuznar, Wayne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Robinson, Jennifer G.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Monoclonal Antibody Reduces LDL-C in Presence of Statin (LAPLACE-2)</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">15-16</style></pages><abstract><style  face="normal" font="default" size="100%">The monoclonal antibody evolocumab (previously AMG 145), which inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), dramatically lowered levels of low-density lipoprotein cholesterol (LDL-C) in Phase 2 clinical trials when administered alone or in combination with a statin, including among patients intolerant of statin therapy, those with familial hypercholesterolemia, and in those treated in a 52-week study [Koren MJ et al. Circulation 2013; Giugliano RP et al. Lancet 2012; Koren MJ et al. Lancet 2012; Raal F et al. Circulation 2012; Sullivan D et al. JAMA 2012]. This article discusses the Phase 3 LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 study [LAPLACE-2; NCT01763866].</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>